Details

Autor(en) / Beteiligte

• Javanian, Mostafa
• Bayani, Masomeh
• Shokri, Mehran
• Sadeghi-Haddad-Zavareh, Mahmoud
• Babazadeh, Arefeh
• Yeganeh, Babak
• Mohseni, Sima
• Mehraeen, Rahele
• Sepidarkish, Mahdi
• Bijani, Ali
• Rostami, Ali
• Shahbazi, Mehdi
• Tabari, Afrooz Monadi
• Shabani, Asieh
• Masrour-Roudsari, Jila
• Hasanpour, Amir Hossein
• Gholinejad, Hossein Emam
• Ghorbani, Hossein
• Ebrahimpour, Soheil

Titel

Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study

Ist Teil von

• Romanian Journal of Internal Medicine, 2020-09, Vol.58 (3), p.161-167

Ort / Verlag

Germany

Erscheinungsjahr

2020

Quelle

MEDLINE

Beschreibungen/Notizen

• In December 2019, China has experienced an outbreak of novel coronavirus disease 2019 (COVID-19). Coronavirus has now spread to all of the continents. We aimed to consider clinical characteristics, laboratory data of COVID-19 that provided more information for the research of this novel virus. We performed a retrospective cohort study on the clinical symptoms and laboratory findings of a series of the 100 confirmed patients with COVID-19. These patients were admitted to the hospitals affiliated to Babol University of Medical Sciences (Ayatollah Rohani, Shahid Beheshti and Yahyanejad hospitals) form 25 February 2020 to 12 March 2020. Nineteen patients died during hospitalization and 81 were discharged. Non-survivor patients had a significantly higher C-reactive protein (CRP) (MD: 46.37, 95% CI: 20.84, 71.90; P = 0.001), white blood cells (WBCs) (MD: 3.10, 95% CI: 1.53, 4.67; P < 0.001) and lower lymphocyte (MD: -8.75, 95% CI: -12.62, -4.87; P < 0.001) compared to survivor patients Data analysis showed that comorbid conditions (aRR: 2.99, 95% CI: 1.09, 8.21, P = 0.034), higher CRP levels (aRR: 1.02, 95% CI: 1.01, 1.03, P = 0.044), and lower lymphocyte (aRR: 0.82, 95% CI: 0.73, 0.93, P = 0.003) were associated with increased risk of death. Based on our findings, most non-survivors are elderly with comorbidities. Lymphopenia and increased levels of WBCs along with elevated CRP were associated with increased risk of death. Therefore, it is best to be regularly assessed these markers during treatment of COVID-19 patients.